Samsca Tablet
Product Images NDC 59148-020

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Samsca (NDC 59148-020). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Otsuka America Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Samsca 15mg Ctn

This is a description of Samsca medication. Samsca tablets contain 15 mg of haptan. It is recommended to store it at 25°C (77°F) and excursions between 15°C -30°C (59°F - 86°F) are permitted. The medication is distributed and marketed by Otsuka America Pharmaceutical, Inc., Foskuil, D 20250. Samsca medication is produced by Otsuka Pharmaceutical Co., Ltd, Togo, 1018535 Japan. It comes in a package of 10 tablets, and each package contains 1 strip with 10 tablets. It is a prescription-only medication, and patients should be given a medication guide along with its distribution.*

FDA Label Image

Samsca 30mg Ctn

This description provides medication information for Samsca (tolvaptan). This medication comes in a package containing 10 tablets, each containing 30 mg of vaptan. The NDC (National Drug Code) for this package is 59148-021-50. The package includes a dosage information leaflet and storage instructions. The medication should be stored at 25°C (77°F), with excursions permitted between 15°C -30°C (59°F - 86°F). Samsca medication is distributed and marketed by Otsuka America Pharmaceutical, Inc. in Rockville, MD. It is important to note that Samsca is a prescription drug and should only be initiated in a hospital setting. Each patient should receive the enclosed medication guide when receiving this medication.*

FDA Label Image

Samsca Chem Structure

FDA Label Image

Samsca Figure 01

FDA Label Image

Samsca Figure 02

This is a clinical study comparing Tolvaptan (at a dosage of 1560 mg) with Placebo in treating a certain condition. The study was conducted with a sample size of 110 people for Tolvaptan and 105 people for Placebo. The study analyzed Mean Serum Sodium levels at different time points: Baseline, 8h, 24h, and 7-Day Follow-Up. The statistical analysis showed a significant improvement with Tolvaptan over Placebo (p<0.0001).*

FDA Label Image

Samsca Figure 03

This appears to be a chart or graph displaying mean serum sodium levels and the effect of Tolvaptan (a medication used to treat low levels of sodium in the blood) on those levels over a period of time. The chart shows a significant improvement in serum sodium levels with Tolvaptan compared to the baseline. There is also mention of a washout week, which may indicate a period of time where the medication was not given to the participants to see if there was any lasting effect on their sodium levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.